Therapeutic Asset Ratings
748 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine
Recurrent Primary Peritoneal Carcinosarcoma
Mayo Clinic
P1/2
CC
(47)
Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine
Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
Mayo Clinic
P1/2
CC
(47)
Ast-301
Breast Cancer
Aston Sci. Inc.
P2
CC
(46)
Bacillus Calmette-Guerin
Prostate Cancer
Cellvax Therapeutics Inc
P2
CC
(46)
Dpx-Survivac
Non-Small Cell Lung Carcinoma
ImmunoVaccine Technologies, Inc. (IMV Inc.)
P2
CC
(46)
GLOBO H-CRM197 VACCINE
Non-small Cell Lung Cancer
OBI Pharma, Inc
P2
CC
(46)
Neoantigen Dendritic Cell Vaccine
Colorectal Cancer
National Cancer Centre, Singapore
P2
CC
(46)
Neoantigen Dna Vaccine
Small Cell Lung Carcinoma
Washington University School of Medicine
P2
CC
(46)
Triadeno Vaccine
Prostate Cancer
National Cancer Institute (NCI)
P2
CC
(46)
uv1
Ovarian Cancer
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
P2
CC
(46)
αdc1 vaccine
Ovarian Cancer
Kalinski, Pawel, MD, PhD
P2
CC
(46)
Modified Vaccinia Virus Ankara Vaccine Expressing P53
Colon Carcinoma
City of Hope Medical Center
P1
CC
(46)
Modified Vaccinia Virus Ankara Vaccine Expressing P53
Rectal Carcinoma
City of Hope Medical Center
P1
CC
(46)
il15-transpresenting wt1-targeted dendritic cell vaccine
Malignant Pancreatic Neoplasm
University Hospital, Antwerp
P1/2
CC
(46)
Personalized Neoantigen Peptide Vaccine
Cancer
Seqker Biosciences, Inc.
P1/2
CC
(46)
a2/4-1bbl melanoma vaccine
Melanoma
Hadassah Medical Organization
P1/2
CC
(45)
Gnos-Pv02
Hepatocellular Carcinoma
Geneos Therapeutics
P1/2
CC
(45)
Individualized Anti-Tumor New Antigen Ineo-Vac-R01
Hepatocellular Carcinoma
Zhejiang University
P1/2
CC
(45)
Individualized Anti-Tumor New Antigen Ineo-Vac-R01
Malignant Pancreatic Neoplasm
Zhejiang University
P1/2
CC
(45)
Individualized Anti-Tumor New Antigen Ineo-Vac-R01
Pancreatic Adenocarcinoma
Zhejiang University
P1/2
CC
(45)
Ineo-Vac-P01
Hepatocellular Carcinoma
Zhejiang University
P1/2
CC
(45)
Ineo-Vac-R01
Advanced Hepatocellular Carcinoma (HCC)
Yinghua Xu
P1/2
CC
(45)
Ineo-Vac-R01
Pancreatic Cancer Metastatic
Zhejiang University
P1/2
CC
(45)
Ineo-Vac-R01
Pancreatic Cancer Resectable
Zhejiang University
P1/2
CC
(45)
Oc-Dc
Ovarian Carcinoma
Centre Hospitalier Universitaire Vaudois
P1/2
CC
(45)
Showing 401 to 425 of 748 assets
Previous
Page 17 of 30
Next
